Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells.

Kotula JW, Pratico ED, Ming X, Nakagawa O, Juliano RL, Sullenger BA.

Nucleic Acid Ther. 2012 Jun;22(3):187-95. doi: 10.1089/nat.2012.0347.

2.

G-quartet oligonucleotide mediated delivery of proteins into photoreceptors and retinal pigment epithelium via intravitreal injection.

Leaderer D, Cashman SM, Kumar-Singh R.

Exp Eye Res. 2016 Apr;145:380-392. doi: 10.1016/j.exer.2016.02.009. Epub 2016 Feb 27.

3.

A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism.

Reyes-Reyes EM, Teng Y, Bates PJ.

Cancer Res. 2010 Nov 1;70(21):8617-29. doi: 10.1158/0008-5472.CAN-10-0920. Epub 2010 Sep 21.

4.

Aptamer-based tumor-targeted drug delivery for photodynamic therapy.

Shieh YA, Yang SJ, Wei MF, Shieh MJ.

ACS Nano. 2010 Mar 23;4(3):1433-42. doi: 10.1021/nn901374b.

PMID:
20166743
5.

Mechanistic studies of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation.

Reyes-Reyes EM, Šalipur FR, Shams M, Forsthoefel MK, Bates PJ.

Mol Oncol. 2015 Aug;9(7):1392-405. doi: 10.1016/j.molonc.2015.03.012. Epub 2015 Apr 9.

6.

Current progress on aptamer-targeted oligonucleotide therapeutics.

Dassie JP, Giangrande PH.

Ther Deliv. 2013 Dec;4(12):1527-46. doi: 10.4155/tde.13.118. Review.

7.

Chimeric nucleolin aptamer with survivin DNAzyme for cancer cell targeted delivery.

Subramanian N, Kanwar JR, Akilandeswari B, Kanwar RK, Khetan V, Krishnakumar S.

Chem Commun (Camb). 2015 Apr 25;51(32):6940-3. doi: 10.1039/c5cc00939a. Epub 2015 Mar 23.

PMID:
25797393
8.

Evaluation of somatostatin and nucleolin receptors for therapeutic delivery in non-small cell lung cancer stem cells applying the somatostatin-analog DOTATATE and the nucleolin-targeting aptamer AS1411.

Holmboe S, Hansen PL, Thisgaard H, Block I, Müller C, Langkjær N, Høilund-Carlsen PF, Olsen BB, Mollenhauer J.

PLoS One. 2017 May 22;12(5):e0178286. doi: 10.1371/journal.pone.0178286. eCollection 2017.

9.

Study of the Function of G-Rich Aptamers Selected for Lung Adenocarcinoma.

Hu J, Zhao Z, Liu Q, Ye M, Hu B, Wang J, Tan W.

Chem Asian J. 2015 Jul;10(7):1519-25. doi: 10.1002/asia.201500187. Epub 2015 May 29.

10.

G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms.

Bates PJ, Reyes-Reyes EM, Malik MT, Murphy EM, O'Toole MG, Trent JO.

Biochim Biophys Acta. 2017 May;1861(5 Pt B):1414-1428. doi: 10.1016/j.bbagen.2016.12.015. Epub 2016 Dec 20. Review.

PMID:
28007579
11.

Tumor targeting with a (99m)Tc-labeled AS1411 aptamer in prostate tumor cells.

Noaparast Z, Hosseinimehr SJ, Piramoon M, Abedi SM.

J Drug Target. 2015;23(6):497-505. doi: 10.3109/1061186X.2015.1009075. Epub 2015 Feb 12.

PMID:
25673264
12.

Chimeric aptamers in cancer cell-targeted drug delivery.

Kanwar JR, Roy K, Kanwar RK.

Crit Rev Biochem Mol Biol. 2011 Dec;46(6):459-77. doi: 10.3109/10409238.2011.614592. Epub 2011 Sep 28. Review.

13.

Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells.

Soundararajan S, Wang L, Sridharan V, Chen W, Courtenay-Luck N, Jones D, Spicer EK, Fernandes DJ.

Mol Pharmacol. 2009 Nov;76(5):984-91. doi: 10.1124/mol.109.055947. Epub 2009 Aug 5.

14.

Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy.

Li X, Zhao Q, Qiu L.

J Control Release. 2013 Oct 28;171(2):152-62. doi: 10.1016/j.jconrel.2013.06.006. Epub 2013 Jun 15. Review.

PMID:
23777885
15.

Selection of DNA aptamers against epidermal growth factor receptor with high affinity and specificity.

Wang DL, Song YL, Zhu Z, Li XL, Zou Y, Yang HT, Wang JJ, Yao PS, Pan RJ, Yang CJ, Kang DZ.

Biochem Biophys Res Commun. 2014 Oct 31;453(4):681-5. doi: 10.1016/j.bbrc.2014.09.023. Epub 2014 Sep 19.

PMID:
25242523
16.

Bioimaging of nucleolin aptamer-containing 5-(N-benzylcarboxyamide)-2'-deoxyuridine more capable of specific binding to targets in cancer cells.

Lee KY, Kang H, Ryu SH, Lee DS, Lee JH, Kim S.

J Biomed Biotechnol. 2010;2010:168306. doi: 10.1155/2010/168306. Epub 2010 Mar 1.

17.

The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells.

Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N, Fernandes DJ.

Cancer Res. 2008 Apr 1;68(7):2358-65. doi: 10.1158/0008-5472.CAN-07-5723.

18.

Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamer-siRNA chimeras.

Lai WY, Wang WY, Chang YC, Chang CJ, Yang PC, Peck K.

Biomaterials. 2014 Mar;35(9):2905-14. doi: 10.1016/j.biomaterials.2013.12.054. Epub 2014 Jan 4.

PMID:
24397988
19.

Improved in vitro efficacy of gold nanoconstructs by increased loading of G-quadruplex aptamer.

Dam DH, Lee RC, Odom TW.

Nano Lett. 2014 May 14;14(5):2843-8. doi: 10.1021/nl500844m. Epub 2014 Apr 3.

20.

Cell-specific aptamer-mediated targeted drug delivery.

Zhou J, Rossi JJ.

Oligonucleotides. 2011 Feb;21(1):1-10. doi: 10.1089/oli.2010.0264. Epub 2010 Dec 23. Review.

Supplemental Content

Support Center